Noémie de Gunzburg

Direct oral anticoagulant neutralization by activated charcoal DOAC-Remove for thrombophilia screening

Rémy Favre, Sara Zia-Chahabi, Yasmina Talb, Noémie de Gunzburg et autres

Favre, Rémy; Zia-Chahabi, Sara; Talb, Yasmina; de Gunzburg, Noémie; Flaujac, Claire Author Information

fr (code pays fourni par la source)

Abstracts

Marie Viprey, Fabienne Genre Volot, Céline Falaise, Guillaume Mourey et autres

International audience

fr (code pays fourni par la source)

Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study

Corentin Orvain, Marie Balsat, Emmanuelle Tavernier, Jean‐Pierre Marolleau et autres

Patients undergoing treatment of acute lymphoblastic leukemia (ALL) are at risk for thrombosis, caused in part by the use of l-asparaginase (L-ASP). Antithrombin (AT) replacement has been suggested to prevent venous thromboembolism (VTE) and thus may increase exposure to ASP. We report …

fr, ch (code pays fourni par la source)

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia

Mathilde Ruggiu, Florence Oberkampf, David Ghez, Pascale Cony‐Makhoul et autres

Although the tyrosine kinase inhibitor (TKI) era has brought great improvement in outcome in chronic myelogenous leukemia (CML), prognosis of accelerated phase or myeloid blast crisis patients or of de novo Philadelphia chromosome-positive acute myeloid leukemia remains poor. We conducted a retrospective …

fr (code pays fourni par la source)

Prevention of Venous Thrombotic Events in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatric-Inspired Protocol - a Graall Study

Corentin Orvain, Marie Balsat, Véronique Lhéritier, Emmanuelle Tavernier et autres

Abstract Background: Patients undergoing treatment for acute lymphoblastic leukemia (ALL) are at risk for thrombosis, in part due to the use of L-asparaginase (L-ASP) and subsequent antithrombine (AT) deficiency. Previous reports showed that patients with venous thrombotic events (VTE) have a lower …

fr, ch (code pays fourni par la source)

Toward a NOTCH1/FBXW7/RAS/PTEN –Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study

Amélie Trinquand, Aline Schmidt, Raouf Ben Abdelali, Jérôme Lambert et autres

PURPOSE: The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL) recently reported a significantly better outcome in T-cell acute lymphoblastic leukemia (T-ALL) harboring NOTCH1 and/or FBXW7 (N/F) mutations compared with unmutated T-ALL. Despite this, one third of patients with N/F-mutated T-ALL …

fr (code pays fourni par la source)

Towards a Purely Oncogenetic Risk Classification of Adult T-ALL: a GRAALL Study

Amélie Trinquand, Aline Schmidt, Raouf Ben Abdelali, Jérôme Lambert et autres

Abstract Abstract 881 T-cell acute lymphoblastic leukemia (T-ALL) represents a heterogeneous group of acute leukemias, which account for 25% of adult ALL. The GRAALL group recently reported a significant improvement in the outcome of BCR-ABL negative adult ALL using an intensified treatment …

fr, ch, be (code pays fourni par la source)

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

Sylvie Castaigné, Cécile Pautas, Christine Terré, Emmanuel Raffoux et autres

fr (code pays fourni par la source)

Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA)

Sylvie Castaigné, Cécile Pautas, Christine Terré, Emmanuel Raffoux et autres

Abstract Abstract 6 Aim. GO is a potent antibody-directed chemotherapy against CD33 antigen. Two MRC and SWOG Phase 3 studies have compared standard CT alone or combined with one single GO infusion (at 3 and 6 mg/m2, respectively) in younger adults with …

fr (code pays fourni par la source)